Barclays PLC Neuro Pace Inc Transaction History

Barclays PLC

$436 Billion
Q2 2025

A detailed history of Barclays PLC transactions in Neuro Pace Inc stock. As of the latest transaction made, Barclays PLC holds 71,672 shares of NPCE stock, worth $770,474. This represents 0.0% of its overall portfolio holdings.

Number of Shares

71,672

Previous 71,672 -0.0%

Holding current value

$770,474

Previous $799,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 13, 2025	BUY	$10.34 - $18.13 $418,852 - $734,410	40,508 Added 129.98%	71,672 $799,000
Q1 2025 May 15, 2025	BUY	$10.04 - $14.94 $35,692 - $53,111	3,555 Added 12.88%	31,164 $383,000
Q4 2024 Feb 13, 2025	BUY	$5.9 - $11.93 $41,158 - $83,223	6,976 Added 33.81%	27,609 $309,000
Q3 2024 Nov 15, 2024	BUY	$6.65 - $8.46 $106,446 - $135,419	16,007 Added 346.02%	20,633 $144,000
Q2 2024 Aug 14, 2024	SELL	$6.38 - $15.33 $58,976 - $141,710	-9,244 Reduced 66.65%	4,626 $35,000
Q1 2024 May 15, 2024	SELL	$9.78 - $17.5 $987 - $1,767	-101 Reduced 0.72%	13,870 $183,000
Q4 2023 Feb 15, 2024	BUY	$5.9 - $10.31 $18,478 - $32,290	3,132 Added 28.9%	13,971 $144,000
Q3 2023 Nov 07, 2023	BUY	$4.0 - $9.73 $42,884 - $104,315	10,721 Added 9085.59%	10,839 $105,000
Q4 2022 Feb 13, 2023	SELL	$1.29 - $3.67 $3,999 - $11,377	-3,100 Reduced 96.33%	118 $0
Q3 2022 Nov 03, 2022	SELL	$3.1 - $5.98 $567 - $1,094	-183 Reduced 5.38%	3,218 $12,000
Q2 2022 Aug 12, 2022	SELL	$4.95 - $8.7 $5,702 - $10,022	-1,152 Reduced 25.3%	3,401 $17,000
Q1 2022 May 16, 2022	BUY	$7.06 - $11.57 $32,144 - $52,678	4,553 New	4,553 $38,000

Others Institutions Holding NPCE

# of Institutions

106

Shares Held

21.4M

Call Options Held

3.14M

Put Options Held

68.6K

View Full List

About NeuroPace Inc

Ticker NPCE
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 24,846,900
Market Cap $267M
Description
NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. The company's RNS system also records continuous brain activity data; and ena...

More about NPCE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account